Recap: Oxford Immunotec Global Q1 Earnings

Shares of Oxford Immunotec Global OXFD remained unaffected at $11.76 after the company reported Q1 results.

Quarterly Results

Earnings per share were down 233.33% over the past year to ($0.20), which missed the estimate of ($0.15).

Revenue of $13,911,000 less by 5.94% from the same period last year, which beat the estimate of $13,450,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Q2 revenue expected between $5,000,000 and $6,000,000.

How To Listen To The Conference Call

Date: May 05, 2020

Time: 10:01 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/g5rzprwm

Price Action

52-week high: $17.77

52-week low: $8.37

Price action over last quarter: down 10.98%

Company Overview

Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.